These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32822482)

  • 1. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
    Castillo JJ; Meid K; Flynn CA; Chen J; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Yang G; Hunter Z; Treon SP
    Blood Adv; 2020 Aug; 4(16):3952-3959. PubMed ID: 32822482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
    Castillo JJ; Meid K; Gustine JN; Dubeau T; Severns P; Hunter ZR; Yang G; Xu L; Treon SP
    Clin Cancer Res; 2018 Jul; 24(14):3247-3252. PubMed ID: 29661775
    [No Abstract]   [Full Text] [Related]  

  • 3. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
    Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 5. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
    Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
    Castillo JJ; Branagan AR; Sermer D; Flynn CA; Meid K; Little M; Stockman K; White T; Canning A; Guerrera ML; Kofides A; Liu S; Liu X; Richardson K; Tsakmaklis N; Patterson CJ; Hunter ZR; Treon SP; Sarosiek S
    Blood; 2024 Feb; 143(7):582-591. PubMed ID: 37971194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
    Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
    J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Meid K; Gustine JN; Leventoff C; White T; Flynn CA; Sarosiek S; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Branagan AR; O'Donnell E; Raje N; Yee AJ; Patterson CJ; Hunter ZR; Treon SP
    Leukemia; 2022 Feb; 36(2):532-539. PubMed ID: 34531537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
    Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
    [No Abstract]   [Full Text] [Related]  

  • 15. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
    Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
    J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
    Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
    Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
    Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
    Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.